Plain-English translation of NCT07417488 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new vaccine approach called Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C that aims to help your immune system fight colorectal or small bowel cancer. You would receive one injection followed by two intravenous doses of the medication over about 12 weeks. This is an early-stage study (Phase 1) designed primarily to understand how safe this treatment is and what the right dose should be.
People with advanced colorectal and small bowel cancers often run out of effective treatment options when standard therapies stop working. This trial is testing whether training your immune system to recognize and attack cancer cells using this vaccine approach could offer a new hope for patients in this situation.
You likely qualify if…
You likely don't qualify if…
You would visit the research center for an initial vaccine injection into your arm, then return for two intravenous infusions about 4 weeks apart. During the first 12 weeks, you'll have frequent blood tests and check-ins to monitor for side effects and how your body is responding. After that, you'll have follow-up visits every 3 months with scans and blood work to track whether the cancer is responding, continuing until your cancer progresses, you start a new cancer treatment, or the study ends.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States